附註:Eresearchtechnology updates 3rd qtr/full year outlook -- Enpath revises guidance for 3rd qtr/remainder of 2004 -- Worldwide analgesic market to reach $75 billion by 2010 -- Bodisen Biotech sees strong 3rd qtr financial performance -- CANGENE reports earnings of 52 cents per share fiscal 2004.
